Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome.

Authors :: Klemann C
Esquivel M
Magerus-Chatinet A
Lorenz MR
Fuchs I
Neveux N
Castelle M
Rohr J
da Cunha CB
Ebinger M
Kobbe R
Kremens B
Kollert F
Gambineri E
Lehmberg K
Seidel MG
Siepermann K
Voelker T
Schuster V
Goldacker S
Schwarz K
Speckmann C
Picard C
Fischer A
Rieux-Laucat F
Ehl S
Rensing-Ehl A
Neven B
Source :: Haematologica [Haematologica] 2017 Feb; Vol. 102 (2), pp. e52-e56. Date of Electronic Publication: 2016 Oct 27.
Publication Year :: 2017

Subjects :: Adolescent
Autoimmune Lymphoproliferative Syndrome genetics
Autoimmune Lymphoproliferative Syndrome immunology
Autoimmune Lymphoproliferative Syndrome pathology
Biomarkers metabolism
Child
Child, Preschool
Disease Progression
Drug Administration Schedule
Fas Ligand Protein genetics
Fas Ligand Protein immunology
Female
Gene Expression Regulation
Humans
Infant
Infant, Newborn
Interleukin-10 genetics
Interleukin-10 immunology
Lymphadenopathy drug therapy
Lymphadenopathy genetics
Lymphadenopathy immunology
Lymphadenopathy pathology
Male
Retrospective Studies
Splenomegaly drug therapy
Splenomegaly genetics
Splenomegaly immunology
Splenomegaly pathology
fas Receptor immunology
Antibiotics, Antineoplastic therapeutic use
Autoimmune Lymphoproliferative Syndrome drug therapy
Immunosuppressive Agents therapeutic use
Sirolimus therapeutic use
fas Receptor genetics

Full Text Access

Tools